Apollomics (APLM) News Today $18.43 +6.25 (+51.34%) As of 10/3/2025 Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock APLM Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Apollomics Inc. (NASDAQ:APLM) Sees Large Decline in Short InterestOctober 3 at 3:21 AM | americanbankingnews.comNasdaq halts ApollomicsSeptember 17, 2025 | msn.comNasdaq Halts Trading of Apollomics Inc. for Additional InformationSeptember 17, 2025 | quiverquant.comQApollomics, Inc. (APLMW) stock price, news, quote & history - Yahoo FinanceJuly 11, 2025 | nz.finance.yahoo.comHong-Jung Chen - APLM | Apollomics Inc. - Wall Street JournalJuly 8, 2025 | wsj.comApollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business ProgressApril 3, 2025 | globenewswire.comApollomics, LaunXP enter development, commercial agreement for VebreltinibMarch 31, 2025 | markets.businessinsider.comApollomics and LaunXP Announce Development and Commercialization Agreement for VebreltinibMarch 31, 2025 | globenewswire.comUS Stock Futures Rise as Investors Await Key Inflation DataFebruary 28, 2025 | msn.comAPLM stock touches 52-week low at $6.38 amid market challengesFebruary 11, 2025 | msn.comBiotech fails trials for its leukemia drugDecember 20, 2024 | bizjournals.comApollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid LeukemiaDecember 20, 2024 | globenewswire.comApollomics Inc trading halted, volatility trading pauseDecember 18, 2024 | markets.businessinsider.comApollomics Regains Compliance with Nasdaq’s Minimum Bid Price RequirementDecember 11, 2024 | markets.businessinsider.comApollomics Regains Compliance with Nasdaq's Minimum Bid Price RequirementDecember 10, 2024 | globenewswire.comApollomics announces approval, date for 1-for-100 reverse share splitNovember 22, 2024 | markets.businessinsider.comApollomics Inc.: Apollomics' Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share SplitNovember 21, 2024 | finanznachrichten.deApollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share SplitNovember 21, 2024 | finance.yahoo.comHyloris Pharmaceuticals SA (52U.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comApollomics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4, 2024 | globenewswire.comFlutter in talks to buy Italy's Snaitech for $2.6B, Sky News reportsAugust 14, 2024 | uk.finance.yahoo.comApollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical ProgressAugust 14, 2024 | globenewswire.comBiotech Sees Massive Buying Pressure Following Phase 2 Preliminary DataAugust 13, 2024 | msn.comApollomics stock rallies 30% on Phase 2 vebreltinib dataAugust 13, 2024 | msn.comApollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA TrialAugust 13, 2024 | globenewswire.comApollomics to Present at the Canaccord Genuity 44th Annual Growth ConferenceAugust 9, 2024 | finance.yahoo.comWhat's Going On With Apollomics (APLM) Stock Exploding Higher?July 19, 2024 | benzinga.comApollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price RequirementJuly 16, 2024 | globenewswire.comApollomics Announces Updated Strategic Focus and Leadership Team ChangesJuly 3, 2024 | globenewswire.comApollomics Announces Presentation at the 2024 BIO International ConventionMay 29, 2024 | finance.yahoo.comMaintaining Buy Rating on Apollomics Amid Clinical Setbacks and Pipeline PotentialMay 8, 2024 | markets.businessinsider.comApollomics Announces Private Placement Financing and Addition to Board of DirectorsMay 8, 2024 | finance.yahoo.comApollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion GeneApril 25, 2024 | globenewswire.comApollomics (APLM) Price Target Decreased by 58.93% to 5.87April 17, 2024 | msn.comApollomics, Inc. (APLM) Interactive Stock Chart - Yahoo FinanceApril 16, 2024 | finance.yahoo.comApollomics, Inc. (NASDAQ:APLM) Sees Large Increase in Short InterestApril 10, 2024 | marketbeat.comApollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual MeetingApril 10, 2024 | globenewswire.comQ1 2024 EPS Estimates for Apollomics, Inc. Decreased by Analyst (NASDAQ:APLM)April 3, 2024 | marketbeat.comApollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual MeetingApril 2, 2024 | finance.yahoo.comHC Wainwright Trims Apollomics (NASDAQ:APLM) Target Price to $5.00April 1, 2024 | marketbeat.comApollomics GAAP EPS of -$2.32March 28, 2024 | msn.comApollomics Highlights Clinical Progress and Reports Full Year 2023 Financial ResultsMarch 28, 2024 | globenewswire.comApollomics (APLM) Set to Announce Quarterly Earnings on ThursdayMarch 27, 2024 | marketbeat.comApollomics Names Matthew Plunkett as Chief Financial OfficerMarch 4, 2024 | finance.yahoo.comApollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial OfficerMarch 4, 2024 | globenewswire.comApollomics Stock (NASDAQ:APLM), Short Interest ReportFebruary 22, 2024 | benzinga.comShort Interest in Apollomics, Inc. (NASDAQ:APLM) Decreases By 54.5%February 12, 2024 | marketbeat.comApollomics (NASDAQ:APLM) Stock Price Down 1.2%February 3, 2024 | marketbeat.comApollomics Inc.: Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyJanuary 20, 2024 | finanznachrichten.deApollomics Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyJanuary 19, 2024 | finance.yahoo.com Get Apollomics News Delivered to You Automatically Sign up to receive the latest news and ratings for APLM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. APLM Media Mentions By Week APLM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APLM News Sentiment▼0.500.54▲Average Medical News Sentiment APLM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APLM Articles This Week▼20▲APLM Articles Average Week Get the Latest News and Ratings for APLM and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Apollomics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Sol-Gel Technologies News Today XBiotech News Today Unicycive Therapeutics News Today Repare Therapeutics News Today OKYO Pharma News Today CervoMed News Today vTv Therapeutics News Today InterCure News Today PMV Pharmaceuticals News Today Sutro Biopharma News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:APLM) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A Millionaire With SEVEN Clicks? $1,000 in just seven stocks in 2004 could have turned into a million-dolla...The Oxford Club | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apollomics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apollomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
